Minotaur Therapeutics

Minotaur Therapeutics is an early-stage biotechnology company developing unique biological therapies for oncology and immunology. Minotaur utilizes a novel ultra-long CDR3 scaffold derived from bovine antibodies with distinctive targeting properties. Minotaur has entered into a licensing and collaboration agreement with the Institute of Applied Biomedical Sciences regarding this emerging therapeutic category and its underlying technology.